June 17th 2024
Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLC
October 21st 2022Dr Mark Socinski reviews the challenges faced when treating chemotherapy induced myelosuppression and discusses the impact of trilaciclib on CIM and how that will impact clinical practice.
Watch
Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion
October 19th 2022During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.
Read More
Greater Understanding of the Biology of NSCLC Propels Treatment Options Forward
October 17th 2022Prior to the 20th Annual Winter Lung Cancer Conference, Mark A. Socinski, MD, spoke with Targeted Therapies in Oncology about expectations for the upcoming meeting and major topics in non–small cell lung cancer.
Read More
Dowlati Compares the Advantages and Disadvantages of Atezolizumab and Durvalumab in ES-SCLC
October 17th 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.
Read More
Roundtable Discussion: Genetic Testing and Treatment in NSCLC With EGFR 19 Exon Deletion
October 13th 2022During a Targeted Oncology case-based roundtable event, Rachel E. Sanborn, MD, discussed with participants the case of a patient with metastatic lung adenocarcinoma with potential targetable biomarkers.
Read More
Roundtable Discussion: Neal Discusses Molecular Testing and Treatment for EGFR Exon 20+ Lung Cancer
October 6th 2022During a case-based roundtable event, Joel W. Neal, MD, PhD of Stanford Cancer Institute and a group of peers discussed using molecular testing to detect an EGFR exon 20 insertion in a patient with lung cancer.
Read More
Dostarlimab Plus Chemo Improves Responses in Patients With Advanced Non-Squamous NSCLC
October 5th 2022Findings from the PERLA trial examining the combination of dostarlimab with pemetrexed followed by cisplatin or carboplatin will be presented at an upcoming medical conference. GSK hints that the combination improves objective response compared with pembrolizumab and chemotherapy.
Read More
FDA Fast Tracks Sapanisertib for NRF2-Mutated Squamous Lung Cancer
October 4th 2022After results from a phase 2 trial demonstrated durability with sapanisertib, the FDA granted fast track designation to the agent for patients with unresectable or metastatic squamous non–small cell lung cancer.
Read More
Latest Recommendations for Broad Molecular Testing in Advanced NSCLC
September 14th 2022During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Read More
Primary End Point of Improved DFS Not Met With Adjuvant Canakinumab in NSCLC
September 12th 2022Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.
Read More
MEDI5752 Plus Chemotherapy Produces Long DOR, But High Dose Comes With High Toxicity
September 11th 2022Chemotherapy added to 1500 mg of MEDI5752, a PD-1/CTLA-4 bispecific monoclonal antibody, led to a doubling in duration of response compared with pembrolizumab and chemotherapy in patients with treatment-naïve nonsquamous non–small cell lung cancer.
Read More
Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic Strategy
September 8th 2022In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.
Read More